Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination–proficient prostate cancer

Journal:

Proceedings of the National Academy of Sciences of the United States of America

Published:

2026-01-27

DOI:

10.1073/pnas.2515790122

Affiliations:

7

Authors:

16

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	13.000000 13.000000	0.81
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	1.000000	0.06
Fred Hutchinson Cancer Center, United States of America (USA)	1.000000	0.06
University of Washington (UW), United States of America (USA)	1.000000	0.06

Interested in Oncology and Carcinogenesis?